Department of Psychiatry, Vanderbilt University Medical Center, 1601 23rd Avenue South, Nashville, TN 37232, USA.
J Autism Dev Disord. 2013 May;43(5):1243-7. doi: 10.1007/s10803-012-1661-2.
We examined response to oxcarbazepine prescribed for irritability/agitation symptoms in a retrospective case series of 30 patients with Autism Spectrum Disorder (ASD). The average patient was 12.0 years old (range 5-21) and taking two other psychotropic medications (range 0-4). Fourteen patients (47 %) had a clinical global impression of improvement score of 'much improved' during treatment. Ten patients (33 %) showed an improvement on their clinical global impression of severity score. Seven patients (23 %) had a clinically significant adverse event or side effect leading to oxcarbazepine discontinuation. Without a placebo group, it is not possible to evaluate whether oxcarbazepine provides benefit for irritability/agitation symptoms in ASD. The high rate of adverse events suggests its use should be accompanied by caution.
我们回顾性地研究了 30 名自闭症谱系障碍（ASD）患者使用奥卡西平治疗烦躁/激越症状的反应。平均患者年龄为 12.0 岁（范围为 5-21 岁），同时服用其他两种精神药物（范围为 0-4 种）。在治疗过程中，有 14 名患者（47%）的临床总体印象改善评分“明显改善”。10 名患者（33%）的临床总体印象严重程度评分有所改善。7 名患者（23%）出现了临床显著的不良事件或副作用，导致奥卡西平停药。由于没有安慰剂组，因此无法评估奥卡西平是否对 ASD 的烦躁/激越症状有益。高不良反应发生率表明其使用应谨慎。
